Compare NAZ & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAZ | CNTB |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.0M | 140.4M |
| IPO Year | 1995 | 2020 |
| Metric | NAZ | CNTB |
|---|---|---|
| Price | $10.98 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 25.4K | ★ 1.7M |
| Earning Date | 01-01-0001 | 08-13-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.99 | $1.06 |
| 52 Week High | $13.42 | $3.82 |
| Indicator | NAZ | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 12.49 | 29.96 |
| Support Level | N/A | N/A |
| Resistance Level | $12.59 | $2.78 |
| Average True Range (ATR) | 0.36 | 0.15 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 0.62 | 0.00 |
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.